A Randomized Controlled Double Blind Trial of Ciclosporin versus Prednisolone in the Management of Leprosy Patients with New Type 1 Reaction, in Ethiopia.
Leprosy Type 1 (T1R) reactions are immune-mediated events leading to nerve damage and preventable disability affecting hands, feet and eyes. Type 1 Reactions are treated with oral corticosteroids. There is little evidence on alternative treatments for patients who do not respond to steroids or exper...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-04-01
|
| Series: | PLoS Neglected Tropical Diseases |
| Online Access: | http://europepmc.org/articles/PMC4821535?pdf=render |
| _version_ | 1818218763038752768 |
|---|---|
| author | Saba M Lambert Digafe T Alembo Shimelis D Nigusse Lawrence K Yamuah Stephen L Walker Diana N J Lockwood |
| author_facet | Saba M Lambert Digafe T Alembo Shimelis D Nigusse Lawrence K Yamuah Stephen L Walker Diana N J Lockwood |
| author_sort | Saba M Lambert |
| collection | DOAJ |
| description | Leprosy Type 1 (T1R) reactions are immune-mediated events leading to nerve damage and preventable disability affecting hands, feet and eyes. Type 1 Reactions are treated with oral corticosteroids. There is little evidence on alternative treatments for patients who do not respond to steroids or experience steroid adverse effects. We report the results of a randomized controlled trial testing the efficacy and adverse effect profile of ciclosporin and prednisolone (CnP) in comparison to prednisolone only (P) in patients with new T1R in Ethiopia. Ciclosporin is a potent immunosuppressant. Outcomes were measured using a clinical severity score, recurrence rate, adverse events and quality of life.Seventy three patients with new T1R were randomized to receive CnP or P for 20 weeks. Recovery rates in skin signs was similar in both groups (91% vs 88%). Improvements in nerve function both, new and old, sensory (66% vs 49%) and motor (75% vs 74%) loss were higher (but not significantly so) in the patients on CnP. Recurrences rates of T1R (85%) were high in both groups, and recurrences occurred significantly earlier (8 weeks) in patients CnP, who needed 10% more additional prednisolone. Serious major and minor adverse events rates were similar in patients in the two treatment arms of the study. Both groups had a significant improvement in their quality of life after the study, measured by the SF-36.This is the first double-blind RCT assessing ciclosporin, in the management of T1R in Africa. Ciclosporin could be a safe alternative second-line drug for patients with T1R who are not improving with prednisolone or are experiencing adverse events related to prednisolone. This study illustrates the difficulty in switching off leprosy inflammation. Better treatment agents for leprosy patients with reactions and nerve damage are needed. |
| first_indexed | 2024-12-12T07:28:55Z |
| format | Article |
| id | doaj.art-6945478e6c254676a089b7d7b6902198 |
| institution | Directory Open Access Journal |
| issn | 1935-2727 1935-2735 |
| language | English |
| last_indexed | 2024-12-12T07:28:55Z |
| publishDate | 2016-04-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Neglected Tropical Diseases |
| spelling | doaj.art-6945478e6c254676a089b7d7b69021982022-12-22T00:33:04ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352016-04-01104e000450210.1371/journal.pntd.0004502A Randomized Controlled Double Blind Trial of Ciclosporin versus Prednisolone in the Management of Leprosy Patients with New Type 1 Reaction, in Ethiopia.Saba M LambertDigafe T AlemboShimelis D NigusseLawrence K YamuahStephen L WalkerDiana N J LockwoodLeprosy Type 1 (T1R) reactions are immune-mediated events leading to nerve damage and preventable disability affecting hands, feet and eyes. Type 1 Reactions are treated with oral corticosteroids. There is little evidence on alternative treatments for patients who do not respond to steroids or experience steroid adverse effects. We report the results of a randomized controlled trial testing the efficacy and adverse effect profile of ciclosporin and prednisolone (CnP) in comparison to prednisolone only (P) in patients with new T1R in Ethiopia. Ciclosporin is a potent immunosuppressant. Outcomes were measured using a clinical severity score, recurrence rate, adverse events and quality of life.Seventy three patients with new T1R were randomized to receive CnP or P for 20 weeks. Recovery rates in skin signs was similar in both groups (91% vs 88%). Improvements in nerve function both, new and old, sensory (66% vs 49%) and motor (75% vs 74%) loss were higher (but not significantly so) in the patients on CnP. Recurrences rates of T1R (85%) were high in both groups, and recurrences occurred significantly earlier (8 weeks) in patients CnP, who needed 10% more additional prednisolone. Serious major and minor adverse events rates were similar in patients in the two treatment arms of the study. Both groups had a significant improvement in their quality of life after the study, measured by the SF-36.This is the first double-blind RCT assessing ciclosporin, in the management of T1R in Africa. Ciclosporin could be a safe alternative second-line drug for patients with T1R who are not improving with prednisolone or are experiencing adverse events related to prednisolone. This study illustrates the difficulty in switching off leprosy inflammation. Better treatment agents for leprosy patients with reactions and nerve damage are needed.http://europepmc.org/articles/PMC4821535?pdf=render |
| spellingShingle | Saba M Lambert Digafe T Alembo Shimelis D Nigusse Lawrence K Yamuah Stephen L Walker Diana N J Lockwood A Randomized Controlled Double Blind Trial of Ciclosporin versus Prednisolone in the Management of Leprosy Patients with New Type 1 Reaction, in Ethiopia. PLoS Neglected Tropical Diseases |
| title | A Randomized Controlled Double Blind Trial of Ciclosporin versus Prednisolone in the Management of Leprosy Patients with New Type 1 Reaction, in Ethiopia. |
| title_full | A Randomized Controlled Double Blind Trial of Ciclosporin versus Prednisolone in the Management of Leprosy Patients with New Type 1 Reaction, in Ethiopia. |
| title_fullStr | A Randomized Controlled Double Blind Trial of Ciclosporin versus Prednisolone in the Management of Leprosy Patients with New Type 1 Reaction, in Ethiopia. |
| title_full_unstemmed | A Randomized Controlled Double Blind Trial of Ciclosporin versus Prednisolone in the Management of Leprosy Patients with New Type 1 Reaction, in Ethiopia. |
| title_short | A Randomized Controlled Double Blind Trial of Ciclosporin versus Prednisolone in the Management of Leprosy Patients with New Type 1 Reaction, in Ethiopia. |
| title_sort | randomized controlled double blind trial of ciclosporin versus prednisolone in the management of leprosy patients with new type 1 reaction in ethiopia |
| url | http://europepmc.org/articles/PMC4821535?pdf=render |
| work_keys_str_mv | AT sabamlambert arandomizedcontrolleddoubleblindtrialofciclosporinversusprednisoloneinthemanagementofleprosypatientswithnewtype1reactioninethiopia AT digafetalembo arandomizedcontrolleddoubleblindtrialofciclosporinversusprednisoloneinthemanagementofleprosypatientswithnewtype1reactioninethiopia AT shimelisdnigusse arandomizedcontrolleddoubleblindtrialofciclosporinversusprednisoloneinthemanagementofleprosypatientswithnewtype1reactioninethiopia AT lawrencekyamuah arandomizedcontrolleddoubleblindtrialofciclosporinversusprednisoloneinthemanagementofleprosypatientswithnewtype1reactioninethiopia AT stephenlwalker arandomizedcontrolleddoubleblindtrialofciclosporinversusprednisoloneinthemanagementofleprosypatientswithnewtype1reactioninethiopia AT diananjlockwood arandomizedcontrolleddoubleblindtrialofciclosporinversusprednisoloneinthemanagementofleprosypatientswithnewtype1reactioninethiopia AT sabamlambert randomizedcontrolleddoubleblindtrialofciclosporinversusprednisoloneinthemanagementofleprosypatientswithnewtype1reactioninethiopia AT digafetalembo randomizedcontrolleddoubleblindtrialofciclosporinversusprednisoloneinthemanagementofleprosypatientswithnewtype1reactioninethiopia AT shimelisdnigusse randomizedcontrolleddoubleblindtrialofciclosporinversusprednisoloneinthemanagementofleprosypatientswithnewtype1reactioninethiopia AT lawrencekyamuah randomizedcontrolleddoubleblindtrialofciclosporinversusprednisoloneinthemanagementofleprosypatientswithnewtype1reactioninethiopia AT stephenlwalker randomizedcontrolleddoubleblindtrialofciclosporinversusprednisoloneinthemanagementofleprosypatientswithnewtype1reactioninethiopia AT diananjlockwood randomizedcontrolleddoubleblindtrialofciclosporinversusprednisoloneinthemanagementofleprosypatientswithnewtype1reactioninethiopia |